Molecular mechanisms of anticancer effect of rutin
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Because of the extensive biological functions of natural substances such as bioflavonoids, and their high safety and low costs, they could have high priority application in the health care system. The antioxidant properties of rutin, a polyphenolic bioflavonoid, have been well documented and demonstrated a wide range of pharmacological applications in cancer research. Since chemotherapeutic drugs have a wide range of side effects and rutin is a safe anticancer agent with minor side effects so recent investigations are performed for study of mechanisms of its anticancer effect. Both in‐vivo and in‐vitro examinations on anticancer mechanisms of this natural agent have been widely carried out. Regulation of different cellular signaling pathways such as Wnt/β‐catenin, p53‐independent pathway, PI3K/Akt, JAK/STAT, MAPK, p53, apoptosis as well as NF‐ĸB signaling pathways helps to mediate the anticancer impacts of this agent. This study tried to review the molecular mechanisms of rutin anticancer effect on various types of cancer. Deep exploration of these anticancer mechanisms can facilitate the development of this beneficial compound for its application in the treatment of different cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ahmad, N., Ahmad, R., Alam, M. A., Ahmad, F. J., & Amir, M. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2018.1489826 · Cited by 46
RetractedTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452 · cited 2×
“…level of reactive oxygen species will probably lead to earlier achievement of cancerous cells to oxidative stress threshold compared to the normal cells, which can subsequently lead to death of cancer cells stimulated by oxidative stress (NavaneethaKrishnan et al., 2018; Trachootham et al., 2009).”
BackgroundWnt signalling in stem cells and cancer
Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666
Integrating cell-signalling pathways with NF-κB and IKK function
Perkins, N. D. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2083 · Cited by 2,350 · cited 1×
“Inactive form of Kappa B (IκB) bound Nuclear Factor-Kappa B (NF-κB) inhibitor has been reported in cytoplasm; nevertheless, its nuclear accumulation is promoted through proteasomal degradation of IκB, which trigger antiapoptotic genes expression (Perkins, 2007).”
BackgroundTargeting JNK for therapeutic benefit: from junk to gold?
Manning, A. M., & Davis, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1132 · Cited by 585 · cited 1×
“Modulation of AP-1activity takes place through extracellular signals consisting of growth factors along with intracellular signaling which is mainly via extracellular-signal-regulated kinase (ERK), p38, and c-Jun N terminal Kinase (Manning & Davis, 2003).”
BackgroundPangeni, R., Sharma, S., Mustafa, G., Ali, J., & Baboota, S. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/48/485102 · Cited by 192
Metadata
- Authors
- Imani, A., Maleki, N., Bohlouli, S., Kouhsoltani, M., Sharifi, S., & Maleki Dizaj, S.
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2020-12-09
- Volume
- 35
- Issue
- 5
- Pages
- 2500-2513
- ISSN
- 0951-418X (ISSN-L)
- 1099-1573
- OpenAlex
- W3111621473
- Cited by
- 240
- References
- 6
- FWCI
- 12.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular mechanisms of anticancer effect of rutin. https://app.cochat.ai/papers/10.1002/ptr.6977
- The paper
- Imani, A., Maleki, N., Bohlouli, S., Kouhsoltani, M., Sharifi, S., & Maleki Dizaj, S. (2021). Molecular mechanisms of anticancer effect of rutin. Phytotherapy Research. https://doi.org/10.1002/ptr.6977
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.